BreastDefend™ prevents breast-to-lung cancer metastases in an orthotopic animal model of triple-negative human breast cancer.
BreastDefend™ prevents breast-to-lung cancer metastases in an orthotopic animal model of triple-negative human breast cancer.
复制标题
DOI：
10.3892/or.2012.1936
复制
发表时间：
2012-10
期刊：
影响因子：
4.2
通讯作者：
Sliva D
中科院分区：
文献类型：
--
作者：
Jiang J;Thyagarajan-Sahu A;Loganathan J;Eliaz I;Terry C;Sandusky GE;Sliva D
我们最近已经证明，天然膳食补充剂BreastDefend（BD），其中含有药用蘑菇提取物（Coriolus versicolor，Ganoderma lucidum，Ganoderma linus linteus），medical herbs（半枝莲、黄芪、姜黄）和纯化的生物活性营养化合物（二吲哚基甲烷和槲皮素）在体外抑制MDA-MB-231侵袭性人乳腺癌细胞的增殖和转移行为。在本研究中，我们评估了BD是否抑制生长和乳腺癌转移到肺癌原位模型的人乳腺癌细胞植入小鼠。经口灌胃给予BD（100 mg/kg体重，持续4周）对小鼠的体重或肝酶活性无影响，且在肝、脾、肾、肺和心脏组织中未显示任何毒性体征。此外，与对照组相比，BD显著降低了肿瘤体积随时间的变化（p=0.002）。BD治疗还显著降低了乳腺癌至肺癌转移的发生率，从67%（对照）降低至20%（BD）（p<0.05），转移的数量从对照组的2.8（0.0，48.0）降低至BD治疗组的0.0（0.0，14.2）（p<0.05）。最后，通过下调乳腺肿瘤中PLAU（尿激酶纤溶酶原激活剂，uPA）和CXCR 4（C-X-C趋化因子受体-4）基因的表达，进一步证实了BD的体内抗转移活性。因此，BD可能被认为是一种针对浸润性乳腺癌的生物治疗剂。
We have recently demonstrated that a natural dietary supplement BreastDefend (BD), which contains extracts from medicinal mushrooms (Coriolus versicolor, Ganoderma lucidum, Phellinus linteus), medicinal herbs (Scutellaria barbata, Astragalus membranaceus, Curcuma longa), and purified biologically active nutritional compounds (diindolylmethane and quercetin), inhibits proliferation and metastatic behavior of MDA-MB-231 invasive human breast cancer cells in vitro. In the present study, we evaluated whether BD suppresses growth and breast-to lung cancer metastasis in an orthotopic model of human breast cancer cells implanted in mice. Oral application of BD (100 mg/kg of body weight for 4 weeks) by intragastric gavage did not affect body weight or activity of liver enzymes and did not show any sign of toxicity in liver, spleen, kidney, lung and heart tissues in mice. Moreover, BD significantly decreased the change in tumor volume over time compared to the control group (p=0.002). BD treatment also markedly decreased the incidence of breast-to-lung cancer metastasis from 67% (control) to 20% (BD) (p<0.05) and the number of metastases from 2.8 (0.0, 48.0) in the control group to 0.0 (0.0, 14.2) in the BD treatment group (p<0.05). Finally, anti-metastatic activity of BD in vivo was further confirmed by the downregulation of expression of PLAU (urokinase plasminogen activator, uPA) and CXCR4 (C-X-C chemokine receptor-4) genes in breast tumors. In conclusion, BD may be considered as a biological therapeutic agent against invasive breast cancers.
登录
查看更多内容
影响因子：
9.7
作者：
Hsu, Erin L.;Chen, Natalie;Hankinson, Oliver
通讯作者：
Hankinson, Oliver
DOI：
10.1186/bcr1006
发表时间：
2005
期刊：
Breast cancer research : BCR
影响因子：
--
作者：
Elliott BE;Meens JA;SenGupta SK;Louvard D;Arpin M
通讯作者：
Arpin M
影响因子：
4.4
作者：
Chen, Nian-Hong;Liu, Jian-Wen;Zhong, Jian-Jiang
通讯作者：
Zhong, Jian-Jiang
影响因子：
4.2
作者：
Kim, Eun Ji;Shin, Minjeong;Park, Jung Han Yoon
通讯作者：
Park, Jung Han Yoon
影响因子：
3.8
作者：
Lee, Wei-Jiunn;Chen, Wen-Kang;Tseng, Tsui-Hwa
通讯作者：
Tseng, Tsui-Hwa